findmyKOL

David Maloney, MD, PhD

Enriched profile

Professor Emeritus, Translational Science and Therapeutics Division · Fred Hutchinson Cancer Center

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Seattle, WA · West · United StatesSpecialtyMedical OncologyFocusCAR-T cell therapy research+4
Active KOLfindmyKOL type: EliteLatest publication2025Online presenceverified 2026Payments2021–2025NIH funding1997–2018

David Maloney is Professor Emeritus, Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center. OpenAlex indexes 843 publications with 54,034 citations (h-index 111); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory. Clarivate lists David Maloney as a Highly Cited Researcher (Clinical Medicine, 2025; Cross-Field, 2022-2024).

Data verified 15 Oct 2026

Overview

Updated 15 Oct 2026

David Maloney is Professor Emeritus, Translational Science and Therapeutics Division at Fred Hutchinson Cancer Center. The public record shows 843 publications with 54,034 citations (h-index 111), centered on CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Hematopoietic Stem Cell Transplantation. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 10 companies, 3 NIH-funded awards (1997–2018).

  • Most recent indexed publication: 2025 · Clinical cancer research
  • Top research focus: CAR-T cell therapy research
  • 14 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 10 companies

Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lymphoma10 trialsLeukemia (AML/ALL/CML/CLL)9 trialsLeukemia, Lymphocytic, Chronic, B-Cell8 trialsLeukemia, Lymphoid8 trialsLymphoma, Non-Hodgkin7 trialsHodgkin Disease7 trialsMultiple Myeloma6 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma6 trialsLymphoma, Follicular6 trialsLymphoma, B-Cell, Marginal Zone6 trialsLymphoma, B-Cell6 trialsWaldenstrom Macroglobulinemia6 trialsBurkitt Lymphoma5 trialsLeukemia, Hairy Cell5 trialsIntraocular Lymphoma5 trialsGranuloma5 trialsLymphomatoid Granulomatosis5 trialsMycosis Fungoides4 trialsSezary Syndrome4 trialsLymphoma, T-Cell, Peripheral4 trialsLymphoma, T-Cell4 trialsLeukemia, T-Cell4 trialsLeukemia, Prolymphocytic3 trialsMDS / MPN3 trialsLeukemia, Myeloid, Acute3 trialsLeukemia, Prolymphocytic, T-Cell2 trialsST Elevation Myocardial Infarction2 trialsAmyloidosis2 trialsImmunoglobulin Light-chain Amyloidosis2 trialsLeukemia, Myelomonocytic, Juvenile2 trialsKidney Cancer / RCC1 trialBlastic Plasmacytoid Dendritic Cell Neoplasm1 trialLeukemia, Prolymphocytic, B-Cell1 trialPrimary Myelofibrosis1 trialPolycythemia Vera1 trialThrombocythemia, Essential1 trialThrombocytosis1 trialPolycythemia1 trialBreast Cancer1 trialCarcinoma, Small Cell1 trial

Research focus

OpenAlex concept fingerprint
CAR-T cell therapy researchLymphoma Diagnosis and TreatmentHematopoietic Stem Cell TransplantationChronic Lymphocytic Leukemia ResearchImmune Cell Function and Interaction

Drugs & molecules

across trials, industry payments and publications
Yescartageneric · Axicabtagene ciloleucelClinical trials—Industry payments5Publications2Kymriahgeneric · TisagenlecleucelClinical trials—Industry payments2Publications—Abecmageneric · Idecabtagene vicleucelClinical trials—Industry payments1Publications—Polivygeneric · Polatuzumab vedotinClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Celgene CorporationClinical trials—Industry payments24E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments24Fred Hutchinson Cancer CenterClinical trials12Industry payments—Kite Pharma, Inc.Clinical trials—Industry payments6Gilead Sciences, Inc.Clinical trials—Industry payments4Incyte CorporationClinical trials—Industry payments3Amgen Inc.Clinical trials—Industry payments2Novartis Pharmaceuticals CorporationClinical trials—Industry payments2bluebird bio, Inc.Clinical trials—Industry payments1Eli Lilly and CompanyClinical trials—Industry payments1Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumClinical trials1Industry payments—Genentech USA, Inc.Clinical trials—Industry payments1SWOG Cancer Research NetworkClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
843publications

Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.

54,034citations

Total citations across indexed works.

111h-index

Hirsch index (OpenAlex). i10-index 362.

Clinical & industry

trials, payments and federal funding
14clinical trials

Investigator role on registered studies.

View trials ↓
10companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
3NIH grants · 1997–2018

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 15 Oct 2026

Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:

All 14 trial records: search, sort and filter.Explore →

Industry payments

Updated 15 Oct 2026

10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 18 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2021)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Dermatology

    57.1%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor57.1%
    Acyclovir100%
    Part D<11 patients

  • Cancer & immunology

    42.9%
    Kinase inhibitor42.9%
    Imbruvica100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 15 Oct 2026

3 NIH research awards on record, funded 1997–2018 per NIH RePORTER. The latest:

All 45 award records: search, sort and filter.Explore →

Congress activity

Updated 15 Oct 2026

127 congress contributions (2004–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:

All 127 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 15 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 10 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
    2,937 citations2005
    doi.org ↗
  2. 02
    Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
    2,344 citations2020
    doi.org ↗
  3. 03
    CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
    2,107 citations2016
    doi.org ↗
  4. 04
    IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
    1,698 citations1997
    doi.org ↗
  5. 05
    Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
    1,395 citations2001
    doi.org ↗
All 843 cited works: search, sort and filter.Explore →

Network

Updated 15 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Rainer Storb227Brenda M. Sandmaier219Ajay K. Gopal148Cameron J. Turtle148Barry E. Storer144Brian G. Till137Thomas R. Chauncey130Stanley R. Riddell117Oliver W. Press116Mazyar Shadman111Michael B. Maris105Jordan Gauthier104Mohamed L. Sorror87Alexandre V. Hirayama87Damian J. Green86Ryan D. Cassaday82Richard T. Maziarz72Michael A. Pulsipher67Cecilia C.S. Yeung66Peter A. McSweeney65Benedetto Bruno62Ted Gooley61John M. Pagel57Aude G. Chapuis53Frederick R. Appelbaum51Dietger Niederwieser50Jenna Voutsinas50Qian Wu47Judith A. Shizuru46Kevin A. Hay45Leona Holmberg44Mary E.D. Flowers44Erik L. Kimble43William Bensinger43Edward Agura42Karl G. Blume41Stephen D. Smith40Hans‐Peter Kiem39Paul J. Martin38Parameswaran Hari37

Online presence

Updated 15 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • ResearchGate

    researchgate.net/scientific-contributions/David-G-Maloney-38866601

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗

Mentions by others

where others cite or feature them
  • X / Twitter

    x.com/mshadman

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 15 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Ph.D. in Cancer Biology

    Stanford University

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
  • M.D.

    Stanford University

    1985
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
  • B.S. in Chemistry and Biochemistry

    Whitworth University

    1977
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
  • Internal Medicine internship/residency

    Brigham and Women's Hospital, Boston

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
  • Medical Oncology Fellowship

    Stanford University Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗

Editorial & leadership roles

journal and society appointments
  • Member

    American Society of Hematology (ASH)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
  • Member

    American Society for Transplantation and Cellular Therapy (ASBMT/ASTCT)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
  • Member

    American Association for Cancer Research (AACR)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • Clinical Medicine
    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
  • Cross-Field
    202220232024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.